Skip to main content
. Author manuscript; available in PMC: 2016 Mar 15.
Published in final edited form as: Growth Factors. 2015 Jun 26;33(3):192–199. doi: 10.3109/08977194.2015.1054990

Figure 2.

Figure 2

Compound 49b improves a-wave and b-wave amplitudes, as well as oscillatory potentials through increasing IGFBP-3 levels. Electroretinogram measurements were made at 2 months of diabetes and after 7 days of treatments in control (Ctrl), diabetic (Diab), diabetic+Compound 49b (diab+49b), diabetic+IGFBP-3 siRNA (Diab+Bp3 siRNA), diabetic+IGFBP-3 siRNA+Compound 49b (Diab+BP3 siRNA+49b) and diabetic+scrambled siRNA (Diab+scsiRNA). *p<0.05 versus control, #p<0.05 versus diabetic, $p<0.05 versus Diab+49b. N=5–6 for all groups. For a-wave, b-wave and oscillatory potentials before measurements, all groups are significantly different than the control.